SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus ...

Retrieved on: 2022-05-28 18:31:52

Tags for this article:

COVID-19 drug development

Monoclonal antibodies

Click the tags to see associated articles and topics

SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus .... View article details on HISWAI: https://www.docwirenews.com/abstracts/sars-cov-2-neutralizing-antibodies-for-covid-19-outcomes-for-bamlanivimab-versus-bamlanivimab-etesevimab-combination-in-a-racially-diverse-cohort-of-patients-with-significant-comorbidities/

Excerpt

WHAT IS KNOWN AND OBJECTIVE: Anti-spike monoclonal antibodies (MAB) including bamlanivimab (BAM) and bamlanivimab/etesevimab (BAM/E) have shown ...

Article found on: www.docwirenews.com

View Original Article